SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Mole SE. Batten's disease: eight genes and still counting. Lancet 1999; 354 4435.
  • 2
    Järvelä I., Autti T., Lamminranta S., Åberg L., Raininko R., Santa-vuori P. Clinical and magnetic resonance imaging findings in Batten disease: analysis of the major mutation (1.02 kb deletion). Ann Neurol 1997; 42 799802.
  • 3
    Järvelä I., Lehtovirta M., Tikkanen R., Kyttala A., Jalanko A. Defective intracellular transport of CLN3 is the molecular basis of Batten disease (JNCL). Hum Mol Genet 1999; 8 10918.
  • 4
    Zeman W., Donohue S., Dyken P., Green J. The neuronal ceroid-lipofuscinoses (Batten-Vogt) syndrome. In: VinkenP., BruynGW. Handbook of Clinical Neurology. Vol X. Leukodystrophies and Poliodystrophies., Amsterdam : North Holland Publishing, 1970; 588679.
  • 5
    Santavuori P., Heiskala H., Westermarck T., Sainio K., Moren R. Experience over 17 years with antioxidant treatment in Spielmeyer-Sjogren disease. Am J Med Genet 1988s uppl 5:265-74.
  • 6
    Hofman I., Kohlschutter A., Santavuori P., et al. CLN3, Juvenile NCL. In: GoebelHH., MoleSE., LakeBD. The Neuronal Ceroid Lipofuscinoses (Batten Disease)., Amsterdam : IOS Press, 1999; 5576.
  • 7
    Kohlschutter A., Laabs R., Albani M. Juvenile neuronal ceroid lipofuscinosis (JNCL): quantitative description of its clinical variability. Acta Pediatr Scand 1988; 77 86772.
  • 8
    Boustany R-M. Neurology of the neuronal ceroid-lipofuscinosis: late infantile and juvenile types. Am J Med Genet 1992; 42 5335.
  • 9
    Proposal for revised clinical and electroencephalographic classification of epileptic seizures: from the Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia 1981; 22 489501.
  • 10
    Palmer D., Fearnely I., Walker J., et al. Mitochondrial ATP synthase subunit c storage in the ceroid-lipofuscinoses (Batten disease). Am J Med Genet 1992; 42 5617.
  • 11
    Spielmeyer W. Weitere mitteilung über eine besondere form von familiärer amaurotischer idiotie. Neurol Cbl 1826; 24 11312.
  • 12
    Sjögren T. Die juvenile amaurotische idiotie. Klinische und erbli-chkeitsmedizinische untersuchungen. Hereditas (Lund) 1931; 14 197426.
  • 13
    Isojärvi J, Laatikainen T, Parkainen A, Juntunen K, Myllyla VV. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 1993; 329 13838.
  • 14
    Åberg L., Kirveskari E., Santavuori P. Lamotrigine therapy in juvenile neuronal ceroid lipofuscinosis. Epilepsia 1999; 40 7969.
  • 15
    Brodie MJ., Yuen AW. Lamotrigine substitution study: evidence for synergism with sodium valproate? 105 Study Group. Epil Res 1997; 26 42332.
  • 16
    Åberg L., Heiskala H., Vanhala S-L, et al. Lamotrigine therapy in infantile neuronal ceroid lipofuscinosis (INCL). Neuropediatrics 1997; 28 779.
  • 17
    Hirvasniemi A., Herrala P., Leisti J. Northern epilepsy syndrome: clinical course and the effect of medication on seizures. Epilepsia 1995; 36 7927.
  • 18
    Gram, L. Valproate.In: Dam, M., GramL. Comprehensive Epileptology., New York : Raven Press, 1990; 53745.
  • 19
    Brodie MJ., Dichter MA. Antiepileptic drugs. NEJM 1990; 334 16875.
  • 20
    Kilpatrick E., Forrest G., Brodie M. Concentration-effect and concentration-toxicity relations with lamotrigine: a prospective study. Epilepsia 1996; 37 534538.
  • 21
    Bardy A., Seppala T., Salokorpi T., Granström M-L, Santavuori P. Monitoring of concentrations of clobazam and norclobazam in serum and saliva of children with epilepsy. Brain Dev 1991; 13 1749.
  • 22
    Berkovic SF., Andermann F., Carpenter S., Wolfe L. Progressive myoclonus epilepsies: specific causes and diagnosis. NEJM 1986; 315 296305.
  • 23
    Lauronen L., Heikkilä E., Autti T., et al. Somatosensory evoked magnetic fields from the primary sensorimotor cortex in patients with juvenile neuronal ceroid lipofusinosis. J Child Neurol 1997; 12 35560.
  • 24
    Boustany R-M, Kolodny EH. The neuronal ceroid-lipofuscinoses: a review. Rev Neurol 1989; 145 10510.
  • 25
    Philippart M., Messa C., Chugani HT. Spielmeyer-Vogt (Batten, Spielmeyer-Sjogren) disease. Distinctive patterns of cerebral glucose utilization. Brain 1994; 117 108592.
  • 26
    Committee on Drugs, 1984 1985. Behavioral and cognitive effects of anticonvulsant therapy. Pediatrics 1985; 76 6447.
  • 27
    Viukari NMA. Intolerance to diphenylhydantoin in five cases of Vogt-Spielmeyer disease. J Ment Defic Res 1969; 13 2458.
  • 28
    Besag FMC. Lamotrigine in the treatment of epilepsy in people with intellectual disability. JTDR 1999; 42 506.